Sign up
Pharma Capital

Q BioMed plans for clinical testing with its autism drug QBM-001

Q BioMed Inc (OTCQB: QBIO) CEO Denis Corin tells Proactive Investors' Christine Corrado the biomedical acceleration and development company is in the middle of preparing for the planned clinical trial of its drug candidate QBM-001, which is being tested to treat pediatric developmental nonverbal disorder in toddlers who suffer from autism spectrum disorders.

Corin added the company has recently reached a $4 million funding agreement with Yorkville Advisors Global, which will allow the biotech to reach additional commercial milestones.

 

View full QBIO profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.